Arbutus Biopharma Corp(ABUS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #570 of 2,961 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
ABUS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Arbutus Biopharma Corp (ABUS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABUS at 64.1/100 on a 32-signal composite quality model, placing it at rank #570 of 2,961 stocks — the top 25% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Arbutus Biopharma Corp reports quarterly revenue of $1.0M, net income of $-5.1M. Top institutional holders of ABUS by reported 13-F value include Two Seas Capital, MORGAN STANLEY, Whitefort Capital Management, based on the most recent SEC filings. ABUS trades on the Nasdaq exchange and files with the SEC under CIK 1447028. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arbutus Biopharma Corp directly from SEC EDGAR. Arbutus Biopharma Corp's 13F Pro composite quality score has ranged between 3 and 64 since 2021, currently 64.1 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.0M
Net Income
Q2 2026
$-5.1M
ROIC
Q2 2026
-9.2%
D/E Ratio
Q2 2026
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+128.2% YoYNet Income
+52.1% YoYOperating Income
+50.0% YoYEPS (Diluted)
+55.3% YoYTotal Assets
-28.2% YoYTotal Debt
Op. Cash Flow
+38.9% YoYFree Cash Flow
+39.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $14.1M +128.2% | $6.2M -66.0% | $18.1M -53.5% | $39.0M +255.1% | $11.0M +58.9% | $6.9M |
| Net Income | $-33.5M +52.1% | $-69.9M +4.0% | $-72.8M -4.9% | $-69.5M +8.9% | $-76.2M -19.6% | $-63.7M |
| Operating Income | $-38.2M +50.0% | $-76.3M +2.3% | $-78.1M -19.3% | $-65.5M +11.0% | $-73.5M -27.2% | $-57.8M |
| EPS (Diluted) | $-0.17 +55.3% | $-0.38 +13.6% | $-0.44 +4.3% | $-0.46 +44.6% | $-0.83 +17.0% | $-1.00 |
| Total Assets | $94.6M -28.2% | $131.7M -8.8% | $144.4M -26.1% | $195.4M -4.4% | $204.5M +49.2% | $137.1M |
| Total Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Operating Cash Flow | $-39.6M +38.9% | $-64.8M +24.5% | $-85.9M -143.1% | $-35.4M +47.6% | $-67.5M -31.3% | $-51.4M |
| Free Cash Flow | $-39.6M +39.1% | $-65.0M +25.2% | $-86.9M -142.4% | $-35.9M +47.5% | $-68.3M -32.3% | $-51.7M |
Get alerted when ABUS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Arbutus Biopharma Corp including:
Top Institutional Holders of ABUS
Two Seas Capital LP
$91.7M19,095,583 shMORGAN STANLEY
$85.0M17,698,305 shWhitefort Capital Management, LP
$75.8M15,794,261 shBlackRock, Inc.
$66.1M13,766,071 shSTATE STREET CORP
$37.8M7,869,179 shRubric Capital Management LP
$36.2M7,532,937 shVANGUARD CAPITAL MANAGEMENT LLC
$33.7M7,010,679 shBARCLAYS PLC
$20.2M4,207,914 shGEODE CAPITAL MANAGEMENT, LLC
$19.8M4,117,691 shGOLDMAN SACHS GROUP INC
$16.8M3,506,802 sh
| Fund | Value | Shares |
|---|---|---|
| Two Seas Capital LP | $91.7M | 19,095,583 |
| MORGAN STANLEY | $85.0M | 17,698,305 |
| Whitefort Capital Management, LP | $75.8M | 15,794,261 |
| BlackRock, Inc. | $66.1M | 13,766,071 |
| STATE STREET CORP | $37.8M | 7,869,179 |
| Rubric Capital Management LP | $36.2M | 7,532,937 |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.7M | 7,010,679 |
| BARCLAYS PLC | $20.2M | 4,207,914 |
| GEODE CAPITAL MANAGEMENT, LLC | $19.8M | 4,117,691 |
| GOLDMAN SACHS GROUP INC | $16.8M | 3,506,802 |
Companies Similar to ABUS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Arcturus Therapeutics Holdings Inc.
uniQure N.V.
Keros Therapeutics, Inc.
Roivant Sciences Ltd.
Xencor Inc
Nurix Therapeutics, Inc.
Personalis, Inc.
ENANTA PHARMACEUTICALS INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ABUS on your watchlist
Track score changes the day Arbutus Biopharma Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ABUS a good stock to buy?
13F Pro's AI-powered analysis of Arbutus Biopharma Corp (ABUS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABUS are available on the ABUS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ABUS is classified as a small company.
Which hedge funds own ABUS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABUS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arbutus Biopharma Corp's investment landscape.